07:36 AM EDT, 07/16/2025 (MT Newswires) -- Voyager Therapeutics ( VYGR ) said Wednesday that it has introduced a new program that modulates the expression of apolipoprotein E, which is the strongest genetic risk factor for Alzheimer's disease.

The program uses a proprietary intravenous-delivered, blood-brain barrier-penetrant Tracer capsid to deliver a payload designed to decrease expression of apolipoprotein E in carriers of the variant APOE4, while delivering the variant APOE2, the company said.

In preclinical studies on mice, the treatment resulted in significant reductions of endogenous APOE4 in key brain regions, the company said.

Voyager said it expects to present early data on the program at an upcoming scientific meeting within the year.